Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Non-Current Assets (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Non-Current Assets readings, the most recent being $146.5 million for Q1 2026.

  • Quarterly Non-Current Assets rose 366.28% to $146.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $458.3 million through Mar 2026, up 357.07% year-over-year, with the annual reading at $120.4 million for FY2025, 912.65% up from the prior year.
  • Non-Current Assets hit $146.5 million in Q1 2026 for Oric Pharmaceuticals, up from $120.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $146.5 million in Q1 2026 and bottomed at $11.9 million in Q4 2024.
  • Average Non-Current Assets over 5 years is $50.7 million, with a median of $36.0 million recorded in 2022.
  • The largest annual shift saw Non-Current Assets plummeted 69.82% in 2024 before it skyrocketed 912.65% in 2025.
  • Oric Pharmaceuticals' Non-Current Assets stood at $36.7 million in 2022, then increased by 7.32% to $39.4 million in 2023, then plummeted by 69.82% to $11.9 million in 2024, then skyrocketed by 912.65% to $120.4 million in 2025, then grew by 21.68% to $146.5 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Non-Current Assets are $146.5 million (Q1 2026), $120.4 million (Q4 2025), and $135.6 million (Q3 2025).